This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations

This study is currently recruiting participants.
See Contacts and Locations
Verified February 2017 by Rune Andersen, Oslo University Hospital
Information provided by (Responsible Party):
Rune Andersen, Oslo University Hospital Identifier:
First received: April 11, 2011
Last updated: February 17, 2017
Last verified: February 2017
The purpose of this study is to determine the effectiveness of bleomycin, fibrovein and bleomycin and fibrovein in the treatment of venous malformation.

Condition Intervention Phase
Venous Malformation Drug: Bleomycin Drug: Fibrovein Drug: Bleomycin + Fibrovein Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations

Resource links provided by NLM:

Further study details as provided by Rune Andersen, Oslo University Hospital:

Primary Outcome Measures:
  • Pain [ Time Frame: 1 year ]
    Pain will be measured before, during and after treatment. It will be asked about type, characteristics and intensity of pain. Using the VAS 0-10 will be used in this matter.

Estimated Enrollment: 126
Study Start Date: August 2011
Estimated Study Completion Date: December 2018
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bleomycin + Fibrovein Drug: Bleomycin + Fibrovein
Other Name: Bleomycin Baxter + Fibrovein pharmaceutical products
Active Comparator: Bleomycin Drug: Bleomycin
Other Name: Bleomycin Baxter
Experimental: Natrium Tetradecyl Sulphate (Fibrovein ) Drug: Fibrovein
Other Name: Fibrovein S.T.D pharmaceutical products LTD

Detailed Description:

Patients with scanty symptoms from their vascular malformation can do well with conservative treatment and / or with aids and adaptations in daily life. Compression therapy (elastic stockings), pain medication and good counseling is adequate for many. Patients with significant symptoms, however, may require more invasive treatment. Previously, it was common with surgical removal, but serious sequelae and frequent recurrence after surgery resulted in caution. Today it is more common with intervention radiology treatment with injection of sclerosing agents into existing malformation. This type of therapy almost always requires repeated treatment sequences, sometimes over several months. Treatment aims to seal blood vessels in the malformation and / or make the patient as possible symptoms. Recurrence occurs frequently and there are many who are not completely free from symptoms. Many patients have chronic problems with pain, wounds, bleeding and / or they have a cosmetically disfiguring condition. Predicting the performance of a specific type of treatment can be very difficult.

Until now, there are some studies that have considered the effect of bleomycin / pingyangmycin (China) and ethanol in the treatment of vascular malformations. To our knowledge there is no prospective or retrospective studies that compare the efficacy and side effects of bleomycin and sodium tetradecyl sulfate (Fibrovein ™) in the treatment of VM.


Ages Eligible for Study:   12 Years to 80 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Venous malformation

Exclusion Criteria:

kidney and lung disease

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01347294

Contact: Rune Andersen, md +91564775

Oslo Universitetssykehus Rikshospitalet Recruiting
Oslo, Norway, 0227
Contact: Rune Andersen, MD    +4723073992   
Sponsors and Collaborators
Oslo University Hospital
Study Director: Andreas Abildgaard, phd Oslo Universitetssykehus, Rikshospitalet
  More Information

Responsible Party: Rune Andersen, Consultant MD, Oslo University Hospital Identifier: NCT01347294     History of Changes
Other Study ID Numbers: 1331TMF
TMF1331 ( Other Identifier: OsloUH )
Study First Received: April 11, 2011
Last Updated: February 17, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Congenital Abnormalities
Antibiotics, Antineoplastic
Antineoplastic Agents processed this record on September 21, 2017